Organogenesis (ORGO) Financials

$2.94 +0.05 (+1.55%)

As of 02:06 PM Eastern

Annual Income Statements for Organogenesis

This table shows Organogenesis' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-0.94	4.95	16
Consolidated Net Income / (Loss)	0.86	4.95	16
Net Income / (Loss) Continuing Operations	0.86	4.95	16
Total Pre-Tax Income	-2.81	10	20
Total Operating Income	-1.28	13	22
Total Gross Profit	366	327	346
Total Revenue	482	433	451
Operating Revenue	482	433	451
Total Cost of Revenue	116	106	105
Operating Cost of Revenue	116	106	105
Total Operating Expenses	368	314	324
Selling, General & Admin Expense	295	270	284
Research & Development Expense	50	44	40
Other Operating Expenses / (Income)	3.96	0.00	0.00
Impairment Charge	19	0.00	0.00
Total Other Income / (Expense), net	-1.52	-2.13	-2.02
Interest Expense	1.54	2.19	2.01
Other Income / (Expense), net	0.02	0.06	-0.01
Income Tax Expense	-3.67	5.45	4.75
Preferred Stock Dividends Declared	1.80	0.00	0.00
Basic Earnings per Share	($0.01)	$0.04	$0.12
Weighted Average Basic Shares Outstanding	131.67M	131.23M	130.07M
Diluted Earnings per Share	($0.01)	$0.04	$0.12
Weighted Average Diluted Shares Outstanding	131.67M	132.75M	132.38M
Weighted Average Basic & Diluted Shares Outstanding	126.83M	131.96M	131.18M

This table shows Organogenesis' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	5.88	12	-17	-2.10	-0.57	3.17	5.32	-2.97	7.49	0.22
Consolidated Net Income / (Loss)	7.67	12	-17	-2.10	-0.57	3.17	5.32	-2.97	7.49	0.22
Net Income / (Loss) Continuing Operations	7.67	12	-17	-2.10	-0.57	3.17	5.32	-2.97	7.49	0.22
Total Pre-Tax Income	10	5.82	-15	-4.34	-1.80	7.64	9.18	-4.63	8.75	1.21
Total Operating Income	10	6.24	-14	-3.85	-1.27	8.05	9.75	-4.00	8.72	1.78
Total Gross Profit	96	88	101	81	72	83	91	81	88	91
Total Revenue	127	115	130	110	100	109	117	108	116	117
Operating Revenue	127	115	130	110	100	109	117	108	116	117
Total Cost of Revenue	31	27	29	29	28	26	26	27	27	26
Operating Cost of Revenue	31	27	29	29	28	26	26	27	27	26
Total Operating Expenses	85	82	115	85	73	75	81	85	80	89
Selling, General & Admin Expense	74	72	77	72	61	64	70	74	68	79
Research & Development Expense	12	10	16	13	12	10	11	11	11	9.58
Total Other Income / (Expense), net	0.03	-0.42	-0.65	-0.49	-0.53	-0.41	-0.57	-0.63	0.03	-0.57
Interest Expense	-0.06	0.47	0.62	0.51	0.50	0.44	0.59	0.65	-0.03	0.57
Other Income / (Expense), net	-0.03	0.05	-0.03	0.02	-0.03	0.03	0.03	0.02	-	0.01
Income Tax Expense	2.58	-6.51	2.50	-2.24	-1.23	4.47	3.86	-1.66	1.27	1.00
Basic Earnings per Share	$0.05	$0.09	($0.13)	($0.02)	-	$0.02	$0.04	($0.02)	$0.06	$0.00
Weighted Average Basic Shares Outstanding	131.67M	132.58M	132.57M	131.86M	131.23M	131.31M	131.29M	131.08M	130.07M	130.90M
Diluted Earnings per Share	$0.05	$0.09	($0.13)	($0.02)	-	$0.02	$0.04	($0.02)	$0.06	$0.00
Weighted Average Diluted Shares Outstanding	131.67M	133.93M	132.57M	131.86M	132.75M	133.42M	133.07M	131.08M	132.38M	132.23M
Weighted Average Basic & Diluted Shares Outstanding	126.83M	132.58M	132.58M	132.57M	131.96M	132.04M	131.31M	131.26M	131.18M	130.92M

This table details how cash moves in and out of Organogenesis' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	32	1.05	-11
Net Cash From Operating Activities	14	31	25
Net Cash From Continuing Operating Activities	14	31	25
Net Income / (Loss) Continuing Operations	0.86	4.95	16
Consolidated Net Income / (Loss)	0.86	4.95	16
Depreciation Expense	14	10	5.85
Amortization Expense	3.40	4.92	12
Non-Cash Adjustments To Reconcile Net Income	42	18	16
Changes in Operating Assets and Liabilities, net	-46	-7.62	-25
Net Cash From Investing Activities	-10	-24	-34
Net Cash From Continuing Investing Activities	-10	-24	-34
Purchase of Property, Plant & Equipment	-10	-24	-34
Net Cash From Financing Activities	28	-5.51	-2.20
Net Cash From Continuing Financing Activities	28	-5.51	-2.20
Repayment of Debt	-68	-5.17	-3.01
Repurchase of Common Equity	-25	0.00	0.00
Issuance of Preferred Equity	121	0.00	0.00
Other Financing Activities, net	0.07	-0.33	0.81
Cash Interest Paid	4.97	5.44	2.65
Cash Income Taxes Paid	6.97	3.05	1.20

This table details how cash moves in and out of Organogenesis' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	41	4.45	1.13	-15	5.51	9.32	0.09	-14	-4.73	-4.92
Net Cash From Operating Activities	11	8.70	4.74	-10	11	17	8.65	-5.08	7.80	5.45
Net Cash From Continuing Operating Activities	11	8.70	4.74	-10	11	17	8.65	-5.08	7.80	5.45
Net Income / (Loss) Continuing Operations	7.67	12	-17	-2.10	-0.57	3.17	5.32	-2.97	7.49	0.22
Consolidated Net Income / (Loss)	7.67	12	-17	-2.10	-0.57	3.17	5.32	-2.97	7.49	0.22
Depreciation Expense	3.62	3.57	3.37	3.07	2.98	2.54	2.23	2.69	1.51	1.46
Amortization Expense	0.83	0.83	0.83	0.90	1.23	1.23	1.23	1.23	8.52	1.22
Non-Cash Adjustments To Reconcile Net Income	3.61	4.66	27	6.47	5.45	4.67	4.43	3.67	-2.18	5.87
Changes in Operating Assets and Liabilities, net	-4.80	-13	-9.54	-19	1.52	5.13	-4.56	-9.71	-7.54	-3.31
Net Cash From Investing Activities	-3.36	-2.57	-1.88	-2.22	-3.32	-5.98	-7.50	-7.56	-11	-10
Net Cash From Continuing Investing Activities	-3.36	-2.57	-1.88	-2.22	-3.32	-5.98	-7.50	-7.56	-11	-10
Purchase of Property, Plant & Equipment	-3.36	-2.57	-1.88	-2.22	-3.32	-5.98	-7.50	-7.56	-11	-10
Net Cash From Financing Activities	34	-1.68	-1.73	-2.61	-1.78	-1.44	-1.05	-1.24	-1.88	0.03
Net Cash From Continuing Financing Activities	34	-1.68	-1.73	-2.61	-1.78	-1.44	-1.05	-1.24	-1.88	0.03
Repayment of Debt	-63	-1.68	-1.67	-1.67	-1.78	-1.44	-1.02	-0.94	-1.88	-
Other Financing Activities, net	1.06	0.01	-0.05	-0.94	0.00	-0.00	-0.03	-0.30	-	0.03
Cash Interest Paid	0.87	1.36	1.37	1.38	1.54	1.29	1.34	1.27	0.86	0.75
Cash Income Taxes Paid	1.47	0.70	4.76	0.04	0.03	-0.00	2.89	0.13	0.23	-

This table presents Organogenesis' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	498	460	449
Total Current Assets	286	225	223
Cash & Equivalents	136	104	102
Restricted Cash	0.58	0.50	0.81
Accounts Receivable	110	82	89
Inventories, net	26	28	25
Prepaid Expenses	14	10	5.09
Plant, Property, & Equipment, net	89	116	102
Total Noncurrent Assets	123	119	124
Goodwill	29	29	29
Intangible Assets	12	16	21
Noncurrent Deferred & Refundable Income Taxes	39	28	30
Other Noncurrent Operating Assets	42	46	45
Total Liabilities & Shareholders' Equity	498	460	449
Total Liabilities	113	181	184
Total Current Liabilities	77	81	75
Short-Term Debt	0.00	19	4.54
Accounts Payable	29	31	32
Accrued Expenses	39	30	26
Other Current Liabilities	9.11	1.08	12
Total Noncurrent Liabilities	35	101	109
Long-Term Debt	0.00	61	66
Capital Lease Obligations	0.72	27	0.00
Other Noncurrent Operating Liabilities	34	13	42
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	122	0.00	-
Total Equity & Noncontrolling Interests	263	279	266
Total Preferred & Common Equity	263	279	266
Preferred Stock	0.00	0.00	0.00
Total Common Equity	263	279	266
Common Stock	303	320	311
Retained Earnings	-40	-41	-45

This table presents Organogenesis' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	446	443	458	463	450	446	457
Total Current Assets	239	234	227	226	216	217	231
Cash & Equivalents	94	90	89	98	89	89	107
Restricted Cash	0.59	0.58	0.72	0.60	0.59	0.72	0.77
Accounts Receivable	101	106	96	89	94	92	93
Inventories, net	27	27	28	28	25	26	25
Prepaid Expenses	15	11	14	9.57	7.95	9.85	4.71
Plant, Property, & Equipment, net	90	90	114	118	112	107	97
Total Noncurrent Assets	118	119	117	120	122	123	130
Goodwill	29	29	29	29	29	29	29
Intangible Assets	13	14	15	17	18	20	22
Noncurrent Deferred & Refundable Income Taxes	36	34	28	30	30	30	32
Other Noncurrent Operating Assets	40	42	45	44	45	44	47
Total Liabilities & Shareholders' Equity	446	443	458	463	450	446	457
Total Liabilities	168	180	180	186	179	182	201
Total Current Liabilities	77	86	83	81	73	76	89
Short-Term Debt	16	17	5.49	5.48	18	17	17
Accounts Payable	24	29	23	27	27	30	38
Accrued Expenses	36	38	40	35	28	29	34
Other Current Liabilities	1.15	1.13	14	14	0.21	0.00	0.00
Total Noncurrent Liabilities	90	94	98	104	106	106	112
Long-Term Debt	56	58	59	62	63	65	68
Capital Lease Obligations	24	25	1.60	2.17	41	40	43
Other Noncurrent Operating Liabilities	11	11	37	40	1.19	1.15	1.09
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	279	264	278	277	271	264	256
Total Preferred & Common Equity	279	264	278	277	271	264	256
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	279	264	278	277	271	264	256
Common Stock	326	324	321	317	315	313	309
Retained Earnings	-48	-60	-43	-40	-44	-49	-53

This table displays calculated financial ratios and metrics derived from Organogenesis' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	11.29%	-3.94%	-3.52%
EBITDA Growth	-43.60%	-30.69%	-54.63%
EBIT Growth	-110.04%	-43.56%	-69.13%
NOPAT Growth	-115.07%	-65.11%	-84.16%
Net Income Growth	-82.59%	-68.16%	-83.51%
EPS Growth	-125.00%	-66.67%	-82.86%
Operating Cash Flow Growth	-54.04%	24.37%	-59.89%
Free Cash Flow Firm Growth	171.89%	-196.94%	504.07%
Invested Capital Growth	-10.96%	20.37%	-9.95%
Revenue Q/Q Growth	5.93%	-3.53%	-2.66%
EBITDA Q/Q Growth	30.03%	-36.05%	-12.63%
EBIT Q/Q Growth	90.09%	-44.11%	-33.13%
NOPAT Q/Q Growth	89.95%	-57.35%	-73.60%
Net Income Q/Q Growth	111.67%	-61.96%	-73.69%
EPS Q/Q Growth	83.33%	-60.00%	-73.33%
Operating Cash Flow Q/Q Growth	2.33%	10.01%	-28.99%
Free Cash Flow Firm Q/Q Growth	173.23%	-198.38%	202.81%
Invested Capital Q/Q Growth	-10.64%	13.25%	-15.54%
Profitability Metrics	-	-	-
Gross Margin	75.99%	75.42%	76.71%
EBITDA Margin	3.27%	6.45%	8.94%
Operating Margin	-0.27%	2.89%	4.95%
EBIT Margin	-0.26%	2.90%	4.94%
Profit (Net Income) Margin	0.18%	1.14%	3.44%
Tax Burden Percent	-30.67%	47.58%	76.58%
Interest Burden Percent	222.25%	82.59%	90.99%
Effective Tax Rate	0.00%	52.42%	23.42%
Return on Invested Capital (ROIC)	-0.34%	2.32%	6.94%
ROIC Less NNEP Spread (ROIC-NNEP)	-2.97%	8.97%	27.66%
Return on Net Nonoperating Assets (RNNOA)	0.60%	-0.50%	-0.82%
Return on Equity (ROE)	0.26%	1.82%	6.13%
Cash Return on Invested Capital (CROIC)	11.26%	-16.17%	17.41%
Operating Return on Assets (OROA)	-0.26%	2.77%	4.99%
Return on Assets (ROA)	0.18%	1.09%	3.48%
Return on Common Equity (ROCE)	0.21%	1.82%	6.13%
Return on Equity Simple (ROE_SIMPLE)	0.33%	1.77%	5.85%
Net Operating Profit after Tax (NOPAT)	-0.90	5.96	17
NOPAT Margin	-0.19%	1.38%	3.79%
Net Nonoperating Expense Percent (NNEP)	2.64%	-6.65%	-20.72%
Return On Investment Capital (ROIC_SIMPLE)	-0.34%	1.55%	5.08%
Cost of Revenue to Revenue	24.01%	24.58%	23.29%
SG&A Expenses to Revenue	61.10%	62.28%	62.94%
R&D to Revenue	10.43%	10.25%	8.82%
Operating Expenses to Revenue	76.26%	72.52%	71.76%
Earnings before Interest and Taxes (EBIT)	-1.26	13	22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	16	28	40
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.61	1.94	1.33
Price to Tangible Book Value (P/TBV)	1.91	2.31	1.63
Price to Revenue (P/Rev)	0.88	1.25	0.78
Price to Earnings (P/E)	0.00	109.21	22.67
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.92%	4.41%
Enterprise Value to Invested Capital (EV/IC)	1.65	1.93	1.37
Enterprise Value to Revenue (EV/Rev)	0.85	1.25	0.71
Enterprise Value to EBITDA (EV/EBITDA)	26.09	19.39	7.93
Enterprise Value to EBIT (EV/EBIT)	0.00	43.08	14.34
Enterprise Value to NOPAT (EV/NOPAT)	0.00	90.94	18.71
Enterprise Value to Operating Cash Flow (EV/OCF)	28.94	17.53	12.86
Enterprise Value to Free Cash Flow (EV/FCFF)	13.77	0.00	7.46
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.38	0.27
Long-Term Debt to Equity	0.00	0.31	0.25
Financial Leverage	-0.20	-0.06	-0.03
Leverage Ratio	1.44	1.67	1.76
Compound Leverage Factor	3.21	1.38	1.60
Debt to Total Capital	0.19%	27.62%	21.03%
Short-Term Debt to Total Capital	0.00%	4.84%	1.35%
Long-Term Debt to Total Capital	0.19%	22.78%	19.69%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	31.71%	0.00%	0.00%
Common Equity to Total Capital	68.10%	72.38%	78.97%
Debt to EBITDA	0.05	3.80	1.76
Net Debt to EBITDA	-8.59	0.07	-0.81
Long-Term Debt to EBITDA	0.05	3.14	1.64
Debt to NOPAT	-0.80	17.84	4.14
Net Debt to NOPAT	150.80	0.33	-1.90
Long-Term Debt to NOPAT	-0.80	14.71	3.88
Altman Z-Score	3.61	3.07	2.57
Noncontrolling Interest Sharing Ratio	18.44%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.69	2.80	2.97
Quick Ratio	3.17	2.31	2.56
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	30	-42	43
Operating Cash Flow to CapEx	141.63%	126.90%	73.33%
Free Cash Flow to Firm to Interest Expense	19.34	-18.96	21.33
Operating Cash Flow to Interest Expense	9.20	14.12	12.37
Operating Cash Flow Less CapEx to Interest Expense	2.70	2.99	-4.50
Efficiency Ratios	-	-	-
Asset Turnover	1.01	0.95	1.01
Accounts Receivable Turnover	5.02	5.05	5.25
Inventory Turnover	4.25	4.02	4.22
Fixed Asset Turnover	4.69	3.96	4.97
Accounts Payable Turnover	3.88	3.38	3.41
Days Sales Outstanding (DSO)	72.64	72.24	69.58
Days Inventory Outstanding (DIO)	85.89	90.90	86.55
Days Payable Outstanding (DPO)	94.03	108.07	107.17
Cash Conversion Cycle (CCC)	64.50	55.07	48.96
Capital & Investment Metrics	-	-	-
Invested Capital	250	281	233
Invested Capital Turnover	1.82	1.69	1.83
Increase / (Decrease) in Invested Capital	-31	47	-26
Enterprise Value (EV)	411	542	320
Market Capitalization	424	540	352
Book Value per Share	$1.98	$2.11	$2.03
Tangible Book Value per Share	$1.67	$1.77	$1.65
Total Capital	386	385	336
Total Debt	0.72	106	71
Total Long-Term Debt	0.72	88	66
Net Debt	-135	1.98	-33
Capital Expenditures (CapEx)	10	24	34
Debt-free, Cash-free Net Working Capital (DFCFNWC)	72	59	49
Debt-free Net Working Capital (DFNWC)	208	163	152
Net Working Capital (NWC)	208	145	148
Net Nonoperating Expense (NNE)	-1.76	1.01	1.55
Net Nonoperating Obligations (NNO)	-135	1.98	-33
Total Depreciation and Amortization (D&A)	17	15	18
Debt-free, Cash-free Net Working Capital to Revenue	15.00%	13.58%	10.83%
Debt-free Net Working Capital to Revenue	43.25%	37.67%	33.74%
Net Working Capital to Revenue	43.25%	33.37%	32.73%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.01)	$0.04	$0.00
Adjusted Weighted Average Basic Shares Outstanding	131.67M	131.23M	0.00
Adjusted Diluted Earnings per Share	($0.01)	$0.04	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	131.67M	132.75M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	126.83M	131.96M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	12	8.77	17
Normalized NOPAT Margin	2.55%	2.02%	3.79%
Pre Tax Income Margin	-0.58%	2.40%	4.50%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-0.82	5.75	11.10
NOPAT to Interest Expense	-0.58	2.72	8.50
EBIT Less CapEx to Interest Expense	-7.32	-5.38	-5.78
NOPAT Less CapEx to Interest Expense	-7.08	-8.40	-8.37
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	2,959.23%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Organogenesis' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	27.10%	6.12%	11.01%	2.17%	-13.73%	-7.13%	-3.36%	10.84%	-9.65%	2.73%
EBITDA Growth	401.75%	-9.75%	-173.47%	366.67%	-84.44%	165.78%	3.23%	-101.26%	-23.65%	-78.74%
EBIT Growth	887.64%	-22.11%	-242.43%	3.75%	-114.84%	352.97%	-17.97%	-3,007.81%	-55.84%	-89.02%
NOPAT Growth	960.92%	295.96%	-272.30%	3.72%	-111.92%	957.81%	-39.52%	-3,025.78%	-86.02%	-98.01%
Net Income Growth	1,448.51%	289.36%	-420.60%	29.27%	-107.60%	1,373.02%	-39.20%	-225.19%	-85.32%	-98.29%
EPS Growth	0.00%	350.00%	-425.00%	0.00%	0.00%	0.00%	-42.86%	-100.00%	-84.62%	-100.00%
Operating Cash Flow Growth	3.04%	-48.04%	-45.20%	-100.16%	36.08%	206.88%	-15.19%	-459.82%	-56.54%	-80.42%
Free Cash Flow Firm Growth	179.38%	-158.95%	175.00%	212.06%	-245.65%	129.77%	67.09%	65.87%	151.01%	-913.57%
Invested Capital Growth	-10.96%	12.85%	-10.35%	-13.99%	20.37%	-10.23%	12.86%	12.02%	-9.95%	62.70%
Revenue Q/Q Growth	9.97%	-11.56%	18.42%	10.36%	-8.18%	-7.49%	8.99%	-6.82%	-1.15%	-3.74%
EBITDA Q/Q Growth	36.86%	210.06%	-6,850.00%	-98.69%	-75.38%	-10.40%	24,600.00%	-100.29%	320.54%	-65.20%
EBIT Q/Q Growth	61.93%	145.22%	-263.54%	-195.90%	-116.01%	-17.31%	345.68%	-145.63%	388.68%	-85.03%
NOPAT Q/Q Growth	-42.14%	235.93%	-260.64%	-203.55%	-126.61%	-40.85%	301.51%	-137.57%	2,262.37%	-96.62%
Net Income Q/Q Growth	-37.77%	172.35%	-711.57%	-269.07%	-117.97%	-40.43%	279.05%	-139.66%	3,381.86%	-97.54%
EPS Q/Q Growth	-44.44%	169.23%	-550.00%	0.00%	0.00%	-50.00%	300.00%	-133.33%	0.00%	-100.00%
Operating Cash Flow Q/Q Growth	25.78%	83.52%	146.62%	-195.75%	-36.57%	93.55%	270.30%	-165.09%	43.04%	-46.51%
Free Cash Flow Firm Q/Q Growth	306.31%	-185.55%	-43.91%	360.11%	-253.21%	208.85%	16.21%	-204.23%	131.32%	-20.32%
Invested Capital Q/Q Growth	-10.64%	2.53%	6.90%	3.23%	13.25%	-18.55%	2.56%	27.23%	-15.54%	2.40%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	75.48%	76.73%	77.58%	73.91%	72.13%	76.24%	77.57%	75.28%	76.53%	77.60%
EBITDA Margin	11.56%	9.29%	-7.46%	0.13%	2.93%	10.92%	11.28%	-0.05%	16.24%	3.82%
Operating Margin	8.07%	5.42%	-10.67%	-3.50%	-1.27%	7.42%	8.31%	-3.72%	7.55%	1.52%
EBIT Margin	8.05%	5.46%	-10.69%	-3.48%	-1.30%	7.45%	8.33%	-3.70%	7.55%	1.53%
Profit (Net Income) Margin	6.06%	10.71%	-13.09%	-1.91%	-0.57%	2.92%	4.53%	-2.76%	6.48%	0.18%
Tax Burden Percent	74.84%	211.76%	117.21%	48.35%	31.66%	41.47%	57.91%	64.17%	85.52%	17.74%
Interest Burden Percent	100.60%	92.52%	104.45%	113.42%	138.87%	94.51%	93.92%	116.31%	100.41%	67.94%
Effective Tax Rate	25.16%	-111.76%	0.00%	0.00%	0.00%	58.53%	42.09%	0.00%	14.48%	82.26%
Return on Invested Capital (ROIC)	10.97%	19.80%	-11.61%	-3.87%	-1.50%	5.27%	7.67%	-4.28%	11.83%	0.56%
ROIC Less NNEP Spread (ROIC-NNEP)	10.93%	26.15%	-46.29%	7.99%	-3.59%	8.94%	6.31%	-4.89%	11.42%	-95.23%
Return on Net Nonoperating Assets (RNNOA)	-2.20%	-1.32%	-3.65%	0.15%	0.20%	-0.16%	0.58%	-0.53%	-0.34%	-0.04%
Return on Equity (ROE)	8.77%	18.49%	-15.26%	-3.72%	-1.30%	5.12%	8.25%	-4.80%	11.49%	0.52%
Cash Return on Invested Capital (CROIC)	11.26%	-15.46%	8.25%	17.54%	-16.17%	16.12%	-8.16%	-5.98%	17.41%	-18.70%
Operating Return on Assets (OROA)	8.10%	5.47%	-10.73%	-3.35%	-1.24%	7.27%	8.40%	-3.87%	7.62%	1.71%
Return on Assets (ROA)	6.10%	10.72%	-13.13%	-1.84%	-0.54%	2.85%	4.57%	-2.88%	6.55%	0.21%
Return on Common Equity (ROCE)	7.16%	18.49%	-15.26%	-3.72%	-1.30%	5.12%	8.25%	-4.80%	11.49%	0.52%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-2.65%	-6.28%	2.09%	0.00%	4.70%	3.70%	5.11%	0.00%	23.03%
Net Operating Profit after Tax (NOPAT)	7.65	13	-9.72	-2.70	-0.89	3.34	5.64	-2.80	7.46	0.32
NOPAT Margin	6.04%	11.48%	-7.47%	-2.45%	-0.89%	3.08%	4.81%	-2.60%	6.45%	0.27%
Net Nonoperating Expense Percent (NNEP)	0.04%	-6.35%	34.69%	-11.86%	2.09%	-3.67%	1.36%	0.62%	0.41%	95.79%
Return On Investment Capital (ROIC_SIMPLE)	2.90%	-	-	-	-0.23%	-	-	-	2.22%	-
Cost of Revenue to Revenue	24.52%	23.27%	22.42%	26.09%	27.87%	23.76%	22.43%	24.72%	23.47%	22.40%
SG&A Expenses to Revenue	58.31%	62.33%	58.77%	65.76%	61.60%	59.17%	59.94%	68.59%	59.12%	67.88%
R&D to Revenue	9.10%	8.98%	11.97%	11.65%	11.81%	9.65%	9.32%	10.41%	9.86%	8.19%
Operating Expenses to Revenue	67.42%	71.32%	88.25%	77.41%	73.41%	68.82%	69.26%	79.00%	68.98%	76.08%
Earnings before Interest and Taxes (EBIT)	10	6.29	-14	-3.83	-1.29	8.08	9.77	-3.98	8.72	1.78
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	15	11	-9.72	0.14	2.92	12	13	-0.05	19	4.46
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.61	1.36	1.41	1.35	1.94	1.51	1.61	1.06	1.33	1.65
Price to Tangible Book Value (P/TBV)	1.91	1.60	1.68	1.60	2.31	1.81	1.94	1.30	1.63	2.06
Price to Revenue (P/Rev)	0.88	0.83	0.83	0.86	1.25	0.93	0.95	0.61	0.78	0.92
Price to Earnings (P/E)	0.00	0.00	0.00	64.46	109.21	32.12	43.37	20.73	22.67	7.18
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	1.55%	0.92%	3.11%	2.31%	4.82%	4.41%	13.92%
Enterprise Value to Invested Capital (EV/IC)	1.65	1.36	1.39	1.38	1.93	1.57	1.54	1.05	1.37	1.61
Enterprise Value to Revenue (EV/Rev)	0.85	0.84	0.85	0.81	1.25	0.87	1.02	0.68	0.71	0.96
Enterprise Value to EBITDA (EV/EBITDA)	26.09	31.37	28.65	9.71	19.39	8.89	12.90	8.68	7.93	9.62
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	27.64	43.08	17.26	28.86	16.95	14.34	13.31
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	50.98	90.94	27.80	41.70	20.78	18.71	6.86
Enterprise Value to Operating Cash Flow (EV/OCF)	28.94	27.39	17.35	13.62	17.53	13.82	27.86	17.00	12.86	12.68
Enterprise Value to Free Cash Flow (EV/FCFF)	13.77	0.00	15.98	7.27	0.00	9.20	0.00	0.00	7.46	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.34	0.38	0.24	0.38	0.25	0.45	0.46	0.27	0.50
Long-Term Debt to Equity	0.00	0.29	0.31	0.22	0.31	0.23	0.38	0.40	0.25	0.43
Financial Leverage	-0.20	-0.05	0.08	0.02	-0.06	-0.02	0.09	0.11	-0.03	0.00
Leverage Ratio	1.44	1.64	1.67	1.67	1.67	1.73	1.72	1.74	1.76	1.86
Compound Leverage Factor	1.45	1.51	1.75	1.89	2.32	1.63	1.62	2.02	1.77	1.26
Debt to Total Capital	0.19%	25.63%	27.46%	19.29%	27.62%	20.13%	31.10%	31.69%	21.03%	33.26%
Short-Term Debt to Total Capital	0.00%	4.29%	4.73%	1.59%	4.84%	1.58%	4.59%	4.45%	1.35%	4.47%
Long-Term Debt to Total Capital	0.19%	21.35%	22.72%	17.70%	22.78%	18.55%	26.51%	27.25%	19.69%	28.79%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	31.71%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	68.10%	74.37%	72.54%	80.71%	72.38%	79.87%	68.90%	68.31%	78.97%	66.74%
Debt to EBITDA	0.05	7.92	7.51	1.83	3.80	1.60	3.37	3.40	1.76	2.77
Net Debt to EBITDA	-8.59	0.09	0.70	-0.63	0.07	-0.66	0.91	0.92	-0.81	0.43
Long-Term Debt to EBITDA	0.05	6.60	6.21	1.68	3.14	1.47	2.87	2.92	1.64	2.40
Debt to NOPAT	-0.80	-10.74	-12.99	9.63	17.84	4.99	10.89	8.14	4.14	1.97
Net Debt to NOPAT	150.80	-0.12	-1.21	-3.32	0.33	-2.08	2.93	2.19	-1.90	0.30
Long-Term Debt to NOPAT	-0.80	-8.94	-10.75	8.83	14.71	4.60	9.29	7.00	3.88	1.71
Altman Z-Score	3.69	2.71	2.36	2.41	2.97	2.63	2.79	2.15	2.47	2.50
Noncontrolling Interest Sharing Ratio	18.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.69	3.09	2.73	2.74	2.80	2.77	2.95	2.85	2.97	2.58
Quick Ratio	3.17	2.53	2.28	2.23	2.31	2.30	2.48	2.38	2.56	2.24
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	38	-19	22	39	-48	32	-29	-35	33	-106
Operating Cash Flow to CapEx	325.41%	338.46%	252.02%	-457.34%	319.31%	279.88%	115.30%	-67.14%	73.20%	52.42%
Free Cash Flow to Firm to Interest Expense	0.00	-39.52	35.10	75.48	-96.19	71.12	-48.84	-53.35	0.00	-185.43
Operating Cash Flow to Interest Expense	0.00	18.46	7.64	-19.77	21.10	37.69	14.56	-7.82	0.00	9.53
Operating Cash Flow Less CapEx to Interest Expense	0.00	13.01	4.61	-24.09	14.49	24.22	1.93	-19.47	0.00	-8.65
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.01	1.00	1.00	0.96	0.95	0.98	1.01	1.05	1.01	1.12
Accounts Receivable Turnover	5.02	4.78	4.49	4.63	5.05	4.92	5.01	5.38	5.25	5.52
Inventory Turnover	4.25	4.09	4.27	4.08	4.02	4.02	4.37	4.41	4.22	4.08
Fixed Asset Turnover	4.69	4.39	4.44	3.94	3.96	4.19	4.46	4.83	4.97	5.39
Accounts Payable Turnover	3.88	4.43	3.93	4.06	3.38	3.27	3.33	3.66	3.41	3.33
Days Sales Outstanding (DSO)	72.64	76.42	81.22	78.86	72.24	74.13	72.80	67.83	69.58	66.07
Days Inventory Outstanding (DIO)	85.89	89.16	85.55	89.48	90.90	90.69	83.51	82.69	86.55	89.47
Days Payable Outstanding (DPO)	94.03	82.37	92.98	90.00	108.07	111.64	109.56	99.77	107.17	109.73
Cash Conversion Cycle (CCC)	64.50	83.22	73.80	78.34	55.07	53.18	46.75	50.76	48.96	45.82
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	250	280	273	255	281	248	304	297	233	276
Invested Capital Turnover	1.82	1.73	1.55	1.58	1.69	1.71	1.59	1.64	1.83	2.08
Increase / (Decrease) in Invested Capital	-31	32	-31	-41	47	-28	35	32	-26	106
Enterprise Value (EV)	411	380	380	352	542	389	469	312	320	444
Market Capitalization	424	379	371	375	540	418	436	279	352	424
Book Value per Share	$1.98	$2.10	$1.99	$2.11	$2.11	$2.11	$2.07	$2.01	$2.03	$1.96
Tangible Book Value per Share	$1.67	$1.78	$1.66	$1.78	$1.77	$1.76	$1.71	$1.64	$1.65	$1.57
Total Capital	386	375	363	344	385	347	394	386	336	384
Total Debt	0.72	96	100	66	106	70	122	122	71	128
Total Long-Term Debt	0.72	80	83	61	88	64	104	105	66	111
Net Debt	-135	1.09	9.25	-23	1.98	-29	33	33	-33	20
Capital Expenditures (CapEx)	3.36	2.57	1.88	2.22	3.32	5.98	7.50	7.56	11	10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	72	82	75	61	59	51	72	69	49	50
Debt-free Net Working Capital (DFNWC)	208	177	166	150	163	150	161	158	152	158
Net Working Capital (NWC)	208	161	148	144	145	144	143	141	148	141
Net Nonoperating Expense (NNE)	-0.03	0.89	7.32	-0.60	-0.32	0.17	0.33	0.17	-0.03	0.10
Net Nonoperating Obligations (NNO)	-135	1.09	9.25	-23	1.98	-29	33	33	-33	20
Total Depreciation and Amortization (D&A)	4.45	4.40	4.20	3.97	4.21	3.77	3.46	3.92	10	2.68
Debt-free, Cash-free Net Working Capital to Revenue	15.00%	18.10%	16.77%	13.90%	13.58%	11.30%	15.64%	14.85%	10.83%	10.88%
Debt-free Net Working Capital to Revenue	43.25%	38.96%	36.95%	34.41%	37.67%	33.31%	35.22%	34.22%	33.74%	34.20%
Net Working Capital to Revenue	43.25%	35.43%	33.11%	33.15%	33.37%	32.09%	31.26%	30.50%	32.73%	30.49%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.05	$0.09	($0.13)	($0.02)	$0.00	$0.02	$0.04	($0.02)	$0.06	$0.00
Adjusted Weighted Average Basic Shares Outstanding	131.67M	132.58M	132.57M	131.86M	131.23M	131.31M	131.29M	131.08M	130.07M	130.90M
Adjusted Diluted Earnings per Share	$0.05	$0.09	($0.13)	($0.02)	$0.00	$0.02	$0.04	($0.02)	$0.06	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	131.67M	133.93M	132.57M	131.86M	132.75M	133.42M	133.07M	131.08M	132.38M	132.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	126.83M	132.58M	132.58M	132.57M	131.96M	132.04M	131.31M	131.26M	131.18M	130.92M
Normalized Net Operating Profit after Tax (NOPAT)	7.65	4.37	3.47	-2.70	-0.89	5.64	5.64	-2.80	7.46	1.25
Normalized NOPAT Margin	6.04%	3.79%	2.66%	-2.45%	-0.89%	5.19%	4.81%	-2.60%	6.45%	1.07%
Pre Tax Income Margin	8.10%	5.06%	-11.16%	-3.95%	-1.80%	7.04%	7.82%	-4.30%	7.58%	1.04%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	13.36	-22.45	-7.45	-2.57	18.20	16.45	-6.13	0.00	3.12
NOPAT to Interest Expense	0.00	28.06	-15.68	-5.25	-1.77	7.52	9.50	-4.32	0.00	0.55
EBIT Less CapEx to Interest Expense	0.00	7.91	-25.48	-11.77	-9.18	4.73	3.83	-17.78	0.00	-15.07
NOPAT Less CapEx to Interest Expense	0.00	22.61	-18.72	-9.57	-8.37	-5.95	-3.12	-15.97	0.00	-17.63
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	2,959.23%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Organogenesis' Financials

When does Organogenesis's fiscal year end?

According to the most recent income statement we have on file, Organogenesis' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Organogenesis' net income changed over the last 2 years?

Organogenesis' net income appears to be on a downward trend, with a most recent value of $861 thousand in 2024, falling from $15.53 million in 2022. The previous period was $4.95 million in 2023. View Organogenesis' forecast to see where analysts expect Organogenesis to go next.

What is Organogenesis's operating income?

Organogenesis's total operating income in 2024 was -$1.28 million, based on the following breakdown:

Total Gross Profit: $366.30 million
Total Operating Expenses: $367.59 million

How has Organogenesis revenue changed over the last 2 years?

Over the last 2 years, Organogenesis' total revenue changed from $450.89 million in 2022 to $482.04 million in 2024, a change of 6.9%.

How much debt does Organogenesis have?

Organogenesis' total liabilities were at $112.57 million at the end of 2024, a 37.9% decrease from 2023, and a 38.7% decrease since 2022.

How much cash does Organogenesis have?

In the past 2 years, Organogenesis' cash and equivalents has ranged from $102.48 million in 2022 to $135.57 million in 2024, and is currently $135.57 million as of their latest financial filing in 2024.

How has Organogenesis' book value per share changed over the last 2 years?

Over the last 2 years, Organogenesis' book value per share changed from 2.03 in 2022 to 1.98 in 2024, a change of -2.3%.

Related Companies

This page (NASDAQ:ORGO) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organogenesis (ORGO) Financials

Frequently Asked Questions About Organogenesis' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organogenesis (ORGO) Financials

Annual Income Statements for Organogenesis

Quarterly Income Statements for Organogenesis

Annual Cash Flow Statements for Organogenesis

Quarterly Cash Flow Statements for Organogenesis

Annual Balance Sheets for Organogenesis

Quarterly Balance Sheets for Organogenesis

Annual Metrics And Ratios for Organogenesis

Quarterly Metrics And Ratios for Organogenesis

Frequently Asked Questions About Organogenesis' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools